VYYRF (Voyageur Pharmaceuticals) EBIT: $-2.41 Mil (TTM As of Feb. 2026)


VYYRF Voyageur Pharmaceuticals Ltd VYYRF
18 GF Score
Price $0.10
! 5 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals EBIT?

Voyageur Pharmaceuticals VYYRF +7.71% 18 EBIT is $-2.41 Mil as of Feb. 2026. GuruFocus rates VYYRF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Voyageur Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2026 was $-0.46 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2026 was $-2.41 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Voyageur Pharmaceuticals's annualized ROC % for the quarter that ended in Feb. 2026 was -97.35%. Voyageur Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -101.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Voyageur Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -12.71%.

Voyageur Pharmaceuticals  (OTCPK:VYYRF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Voyageur Pharmaceuticals's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=-1.836 * ( 1 - 0% )/( (1.854 + 1.918)/ 2 )
=-1.836/1.886
=-97.35 %

where

Invested Capital(Q: Nov. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.209 - 1.221 - ( 0.19 - max(0, 1.29 - 0.424+0.19))
=1.854

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.161 - 1.616 - ( 0.056 - max(0, 1.676 - 0.303+0.056))
=1.918

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Voyageur Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.836/( ( (1.775 + max(-1.056, 0)) + (1.847 + max(-1.4, 0)) )/ 2 )
=-1.836/( ( 1.775 + 1.847 )/ 2 )
=-1.836/1.811
=-101.38 %

where Working Capital is:

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.095 + 0.035 + 0.104) - (1.221 + 0.069 + 0)
=-1.056

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.122 + 0.1 + 0.025) - (1.616 + 0.032 + -0.0010000000000001)
=-1.4

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Voyageur Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2026 )
=-2.413/18.985
=-12.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals EBIT Related Terms

Voyageur Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Voyageur Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals EBIT Chart

Voyageur Pharmaceuticals Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.63 -1.30 -1.02 -1.22 -2.51

Voyageur Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -0.39 -0.95 -0.62 -0.46

VYYRF vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyageur Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's EV-to-EBIT falls into.


VYYRF
18GF Score
Voyageur Pharmaceuticals Ltd VYYRF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyageur Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-2.41 Mil mean?
Voyageur Pharmaceuticals (VYYRF) has a EBIT of $-2.41 Mil as of Feb. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Voyageur Pharmaceuticals.
Is Voyageur Pharmaceuticals' EBIT too high?
Voyageur Pharmaceuticals' current EBIT is $-2.41 Mil. Overall, Voyageur Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' EBIT compare to ZTS and UTHR?
Voyageur Pharmaceuticals' EBIT of $-2.41 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Voyageur Pharmaceuticals. Voyageur Pharmaceuticals's current EBIT is $-2.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current EBIT of $-2.41 Mil. The current EBIT is $-2.41 Mil. Voyageur Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current EBIT is $-2.41 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
18GF Score

Get the complete analysis for VYYRF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price